Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2

Journal of Dermatological Treatment

Volumn 25, Issue 5, 2014, Pages 401-408

  Ma, Chelsea ^a   Armstrong, April W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunomodulatory agents; Melanoma; Toxicity

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; IPILIMUMAB; RECOMBINANT INTERLEUKIN 2; VEMURAFENIB;

ADVANCED CANCER; ANURIA; CANCER STAGING; COLITIS; DEPRESSION; DIARRHEA; DRUG SAFETY; DYSPNEA; ENDOCRINE DISEASE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HYPOTENSION; INCIDENCE; INFECTION; INTESTINE PERFORATION; KERATOACANTHOMA; LIVER DISEASE; LUNG TOXICITY; MELANOMA; MELANOMA METASTASIS; MULTIPLE CYCLE TREATMENT; OLIGURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SKIN CARCINOMA; SKIN DISEASE; SYSTEMATIC REVIEW; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DACARBAZINE; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84890417671     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.813897     Document Type: Review

References (110)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2009. (Vintage 2009 Populations). 2012. Available from http://seer.cancer.gov/ csr/19752009pops09/.
2. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598
3. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:41-48
4. Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C, Giannarelli D, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer immunol. Immunother. 2011;60:467-477
5. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204
6. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2011;29:489-498
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723
8. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter singlearm phase II study. Ann Oncol. 2010;21:1712-1717
9. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956
10. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-164
11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516
12. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819
13. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714
14. Dummer R, Garbe C, Thompson JA, Eggermont AM, Yoo K, Maier T, et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol. 2006;24:1188-1194
15. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117-126
16. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19:1195-1201
17. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomised phase 3 trial. Lancet Oncol. 2011;12:144-152
18. Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clinical Oncol. 2010;28:841-846
19. Hofmann MA, Kiecker F, Kuchler I, Kors C, Trefzer U. Serum TNFalpha, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-alpha2b treatment of patients with melanoma. J Cancer Res Clin Oncol. 2011;137:455-462
20. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009;19:42-49
21. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, et al. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alpha-2b in high-risk acral melanoma patients. Eur J Cancer. 2011; 47:1498-1503
22. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27:939-944
23. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol. 2004;22:1118- 1125
24. Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787-793
25. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751
26. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16:1743-1751
27. Middleton M, Hauschild A, Thomson D, Anderson R, Burdette- Radoux S, Gehlsen K, et al. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol. 2007;18:1691-1697
28. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166
29. Patel PM, Suciu S, Mortier L, Fierlbeck G, Tilgen W, Seiter S, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47:1476-1483
30. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-570
31. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116
32. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993;11:1969-1977
33. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007;25:3802-3807
34. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11
35. Lin R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy. Paper presented at: ASCO Annual Meeting; 2008
36. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm. 2009;24:321-325
37. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic Tlymphocyte- Associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538-2540
38. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30:316-312
39. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-215
40. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, et al. Skin tumors induced by sorafenib; paradoxic RASRAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012;18:263-272
41. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431-435
42. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427-430
43. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 2010;23:190-200
44. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, et al. Practical guidelines for the management of interferon- Alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer. 2008;112:982-994
45. Rubin KM, Vona K, Madden K, McGettigan S, Braun IM. Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: A nurse's perspective. Support Care Cancer. 2012;20:1601-1611
46. Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, et al. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics. 2010;51:466-473
47. Heinze S, Egberts F, Rotzer S, Volkenandt M, Tilgen W, Linse R, et al. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: Results from the multicenter DeCOG trial. J Immunother. 2010; 33:106-114
48. Navines R, Gomez-Gil E, Puig S, Baeza I, De Pablo J, Martin- Santos R. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: Primary to induced disorders. Eur J Dermatol. 2009;19:611-615
49. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652
50. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Mol psychiatry. 2007;12:988-1000
51. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol psychiatry. 2002;7:468-473
52. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol. 1991;294:425- 435
53. Van Gool AR, van Ojik HH, Kruit WH, Bannink M, Mulder PG, Eggermont AM, et al. Pegylated interferon-alpha2b treatment in melanoma patients: Influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. Anticancer Drugs. 2004;15: 587-591
54. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry. 1994;51:865-874
55. Cowen PJ, Power AC, Ware CJ, Anderson IM. 5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone. Br J Psychiatry. 1994;164:372-379
56. McBride PA, Brown RP, DeMeo M, Keilp J, Mieczkowski T, Mann JJ. The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior. Biol Psychiatry. 1994;35:295-308
57. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995;45:947-950
58. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology. 1991;41:672- 676
59. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997;747:348-351
60. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, et al. Escitalopram for the Prevention of Peginterferon-alpha2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease: A Randomized Trial. Ann Intern Med. 2012;157: 94-103
61. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793-798
62. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacol Ther. 2007;25:1163-1174
63. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966
64. Ganiere V, Christen G, Bally F, Guillou L, Pica A, de Ribaupierre S, et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nature Clin Pract Oncol. 2006;3:339- 343; quiz following 343
65. Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma. Eur J Cancer. 1993;29A:711-719
66. Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity. Eur J Cancer. 1992;28:447-450
67. Yoon JM, Rao U, Vassilopoulos PP, Ledesma E, Mittelman A. Interstitial pneumonitis associated with mitomycin C and DTIC: A case report. Med Pediatr Oncol. 1981;9:61-67
68. Maldonado F, Limper AH, Lim KG, Aubrey MC. Temozolomideassociated organizing pneumonitis. Mayo Clin proc. 2007;82:771-773
69. Grafstrom RC, Pegg AE, Trump BF, Harris CC. O6-alkylguanine- DNA alkyltransferase activity in normal human tissues and cells. Cancer Res. 1984;44:2855-2857
70. Gerson SL, Trey JE, Miller K, Berger NA. Comparison of O6- Alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis. 1986;7: 745-749
71. Irwan YY, Feng Y, Gach HM, Symanowski JT, McGregor JR, Veni G, et al. Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain. J Immunol Methods. 2009;349:45-55
72. Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, Gaspari AA, et al. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol. 1988;140:1883-1888
73. Hibbs JB Jr, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clinl Invest. 1992;89:867-877
74. Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother. 2011;34:419-427
75. Palmer RM, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol. 1992;105:11-12
76. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998;273: 25804-25808
77. Samlowski WE, Petersen R, Cuzzocrea S, Macarthur H, Burton D, McGregor JR, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin- 2 and increases its antitumor effects. Nat Med. 2003;9:750-755
78. Kondapaneni M, McGregor JR, Salvemini D, Laubach VE, Samlowski WE. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice. J Immunother. 2008;31:325-333
79. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16:11-20
80. Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM, et al. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol. 1994;15:22-28
81. Ipilimumab, approval letter. In: U.S. Food and Drug Administration CfDEaR, edMarch 25, 2011
82. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614-2627
83. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100:8372-8377
84. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA. 2011;108:266-271
85. Yervoy [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011
86. Vemurafenib, approval letter. In: U.S. Food and Drug Administration CfDEaR, edAugust 17, 2011
87. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell. 2009;33:237-247
88. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954
89. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010;70: 5518-5527
90. Zelboraf [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2011
91. Sylatron, approval letter. In: U.S. Food and Drug Administration CfDEaR, edMarch 29, 2011
92. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21:1251-1262
93. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ. 1997;8:343-352
94. Deblandre GA, Marinx OP, Evans SS, Majjaj S, Leo O, Caput D, et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem. 1995; 270:23860-23866
95. Krepler C, Certa U, Wacheck V, Jansen B, Wolff K, Pehamberger H. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol. 2004;123:664-669
96. Sylatron [package insert]. Kenilworth, NJ: Schering Corporation 2011
97. FDA Approved Drug Products - Dacarbazine. Available from http:// www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Overview&DrugName=DACARBAZINE. Accessed August 1, 2012
98. Lonn U, Lonn S, Nylen U, Winblad G. Reduced DNA damage induced in human melanoma cells by dacarbazine in the presence of deoxyribonucleosides. Cancer Res. 1989;49:2921-2924
99. Lonn U, Lohn S. Prevention of dacarbazine damage of human neoplastic cell DNA by aphidicolin. Cancer Res. 1987;47:26-30
100. Beal DD, Skibba JL, Whitnable KK, Bryan GT. Effects of 5-(3,3- dimethyl-1-triazeno)imidazole-4-carboxamide and its metabolites on Novikoff hepatoma cells. Cancer Res. 1976;36:2827-2831
101. Dacarbazine [package insert]. Irvine, CA: Teva Parenteral Medicines, Inc.; 2007
102. FDA Approved Drug Products - Aldesleukin. Available from http:// www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails.Accessed August 8, 2012
103. Choi KS, Song EK, Yim CY. Cytokines secreted by IL-2-activated lymphocytes induce endogenous nitric oxide synthesis and apoptosis in macrophages. J Leukoc Biol. 2008;83:1440-1450
104. Itoh K, Tilden AB, Balch CM. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol. 1986;136:3910- 3915
105. Kwak JY, Han MK, Choi KS, Park IH, Park SY, Sohn MH, et al. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol. 2000;203:84-94
106. Ohira M, Nishida S, Tryphonopoulos P, Tekin A, Selvaggi G, Moon J, et al. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. Cell transplant. 2012;21(7):1397-1406
107. Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, et al. Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery. 2012;152:431-440
108. Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, et al. Radio frequency ablation combined with interleukin-2- induces an antitumor immune response to renal cell carcinoma in a murine model. J Urol. 2012;188:607-614
109. Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol. 1987;5:1933-1941
110. Aldesleukin [package insert]. Emeryville, CA: Bayer HealthCare Pharmaceuticals, Inc.; 2008